Development of a Novel Drug for Neurodegenerative Disease and Migraine

Technology #ua16-046

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Robin Polt
Professor, Chemistry & Biochemistry
Evan Jones
Graduate Assistant, Chemistry & Biochemistry
Bobbi Anglin
Instructor, CBC
Michael Heien
Associate Professor, Chemistry & Biochemistry
John Streicher
Managed By
Paul Eynott
Sr. Licensing Manager (520) 621-2878

Title: Development of a novel drug for neurodegenerative disease and migraine

Invention: The invention is the development of pituitary adenylate cyclase activating peptide (PACAP) agonists for neuroprotection and antagonists for migraine.

 

Background: PACAP is known as a neuronal survival factor, regulating the development, maintenance, function, and plasticity of neurons through activating PAC1, VPAC1, and VPAC2 receptors. Glycosylated PACAP analogues have been found to penetrate the blood-brain barrier (BBB) at a high rate. In addition, VPAC1/2 receptors are involved in vasodilation and may contribute to migraine attacks. It is possible to treat these migraine attacks by using PACAP antagonists.

 

Applications:

  • A novel drug compound for the treatment of Parkinson’s disease and other neurodegenerative diseases
  • May provide a novel technique to improve BBB permeability

 

Advantages:

  • Improves BBB permeability 
  • Possible treatment of migraines
  • Accessing the central nervous system (CNS) through the BBB may provide better treatment options

 

Licensing Manager:

Rakhi Gibbons

RakhiG@TLA.arizona.edu

(520) 626-6695